Last reviewed · How we verify
AMG 386 and Trastuzumab
AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells.
AMG 386 is an angiopoietin-2 (Ang-2) inhibitor that works by binding to Ang-2 and preventing it from interacting with its receptor, thereby inhibiting angiogenesis. Trastuzumab is a monoclonal antibody that targets the HER2/neu receptor, which is overexpressed in certain cancer cells. Used for Locally advanced or metastatic breast cancer with HER2 overexpression, Locally advanced or metastatic gastric cancer with HER2 overexpression.
At a glance
| Generic name | AMG 386 and Trastuzumab |
|---|---|
| Also known as | AMG 386 (Trebananib); Trastuzumab (Herceptin) |
| Sponsor | QuantumLeap Healthcare Collaborative |
| Drug class | Angiopoietin-2 inhibitor, HER2/neu receptor antagonist |
| Target | Ang-2, HER2/neu |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting Ang-2, AMG 386 reduces the formation of new blood vessels that tumors need to grow. Trastuzumab binds to the HER2/neu receptor on cancer cells, marking them for destruction by the immune system. This dual mechanism of action may help to slow or stop the growth of certain types of cancer.
Approved indications
- Locally advanced or metastatic breast cancer with HER2 overexpression
- Locally advanced or metastatic gastric cancer with HER2 overexpression
Common side effects
- Fatigue
- Nausea
- Diarrhea
- Headache
- Infection
Key clinical trials
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AMG 386 and Trastuzumab CI brief — competitive landscape report
- AMG 386 and Trastuzumab updates RSS · CI watch RSS
- QuantumLeap Healthcare Collaborative portfolio CI